These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 24025585)

  • 1. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
    Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
    Sancho RM; Law BM; Harvey K
    Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GTPase function of LRRK2.
    Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRRK2 pathobiology in Parkinson's disease.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Parkinson disease gene LRRK2: evolutionary and structural insights.
    Marín I
    Mol Biol Evol; 2006 Dec; 23(12):2423-33. PubMed ID: 16966681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.
    Daniëls V; Vancraenenbroeck R; Law BM; Greggio E; Lobbestael E; Gao F; De Maeyer M; Cookson MR; Harvey K; Baekelandt V; Taymans JM
    J Neurochem; 2011 Jan; 116(2):304-15. PubMed ID: 21073465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
    Guo L; Wang W; Chen SG
    Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.
    Deng J; Lewis PA; Greggio E; Sluch E; Beilina A; Cookson MR
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1499-504. PubMed ID: 18230735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.